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lines with HER2/3 overexpression
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Abstract
Background: Elevated basal, ligand-independent, Wnt signaling in some canine breast cancer cells is not caused by
classical mutations in APC, β-Catenin or GSK3β but, at least partially, by enhanced LEF1 expression. We examined
the expression and function of EGFR/HER-regulated pathways on the ligand-independent Wnt signaling.
Methods: Twelve canine mammary tumor cell lines with previously reported differential basal Wnt activity were used.
The expression levels of genes related to EGF-signaling were analyzed by cluster analysis. Cell lines with a combined
overexpression of EGF-related genes and enhanced basal Wnt activity were treated with PI3K/mTor or cSRC inhibitors
or transfected with a construct expressing wild-type PTEN. Subsequently, effects were measured on Wnt activity, cell
proliferation, gene expression and protein level.
Results: High basal Wnt/LEF1 activity was associated with overexpression of HER2/3, ID1, ID2, RAC1 and HSP90 together
with low to absent cMET and PTEN mRNA expression, suggesting a connection between Wnt- and HER-signaling
pathways. Inhibition of the HER-regulated PI3K/mTor pathway using the dual PI3K/mTor inhibitor BEZ235 or the mTor
inhibitor Everolimus® resulted in reduced cell proliferation. In the cell line with high basal Wnt activity, however, an
unexpected further increased Wnt activity was found that could be greatly reduced after inhibition of the HER-regulated
cSRC activity. Inhibition of the PI3K/mTor pathway was associated with enhanced expression of β-Catenin, Axin2, MUC1,
cMET, EGFR and HER2 and a somewhat increased β-Catenin protein content, whereas cSRC inhibition was associated
with slightly enhanced HER3 and SLUG mRNA expression. A high protein expression of HER3 was found only in a cell
line with high basal Wnt activity.
Conclusions: High basal Wnt activity in some mammary cancer cell lines is associated with overexpression of HER-
receptor related genes and HER3 protein, and the absence of PTEN. Inhibition of the PI3K/mTor pathway further
stimulated, however, canonical Wnt signaling, whereas the inhibitory effect with the cSRC inhibitor Src-I1 on the Wnt
activity further suggested a connection between Wnt and HER2/3-signaling.
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Background
Progesterone-induced Wnt signaling plays an important
role in the development of the mammary gland during
puberty, but may also induce the development of mam-
mary tumors from stem/progenitor cells [1]. There is a
high incidence of active Wnt signaling in basal-like
breast cancers [2]. Since this activity cannot always be
explained by overexpression of Wnt ligand or mutations
in players involved in the destruction complex of β- Ca-
tenin alone [3], this high Wnt signaling must have
additional causes. One potential candidate, cytoplasmic
β-Catenin, functions as a key signaling intermediate in
the canonical Wnt/β-Catenin pathway. Wnt proteins, by
binding to membrane receptors on the cell membrane,
initiate the signal transduction. The total Wnt group
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consists of multiple genes that are either canonical
(Wnt 1, 3A, 8A, 8B) or non-canonical (Wnt 5A, 4, 11).
Wnt can also stimulate alternative effectors in the non-
canonical pathway that can antagonize the canonical
pathway [3].
Without a Wnt signal, the β-Catenin destruction com-
plex binds and phosphorylates non-cadherin-associated
β-Catenin. This targets it for destruction by the prote-
asome, thereby allowing TCF family of transcriptional
factors to bind to transcriptional repressors in the nu-
cleus. The destruction complex is disrupted when active
Wnt signaling is stimulated by binding of Wnt proteins
to its Frizzled receptor on the cell membrane. As a re-
sult β-Catenin accumulates in the cytoplasm, translo-
cates to the nucleus and associates with TCF family of
proteins, enhancing transcriptional activation of a pro-
gram of genes [3–5].
In the non-canonical Wnt pathway, Wnt can act
through ROR and RYK tyrosine kinases, which activate
Jun N-terminal kinase (JNK). This increases intercellular
Ca2+ leading to activation of nuclear factor activated T
cells (NFAT) and consequently inhibition of the canon-
ical signaling. The alternative Wnt receptor RYK add-
itionally signals through Dishevelled to cSRC in axon
guidance. Traditionally Wnt ligands do not signal
through β-Catenin in the non-canonical pathway, but it
seems that Wnt 5A had some inhibitory characteristics
on the canonical signaling. Likely there is some crosstalk
between the canonical and the non-canonical Wnt path-
ways [4].
The major drivers of breast cancer risk are 17ß-estradiol
(E2) and progesterone (P4). Synthetic progestins are fre-
quently given as oral anticonception or in hormone re-
placement therapy (HRT) [6, 7]. Apart from stimulating
the expression of Wnt4 [3] P4 decreases the presence of
the ß-catenin binding adhesion protein E-cadherin, which
may result in higher Wnt/β-Catenin signaling [8]. P4 also
affects the non-canonical signaling through the transcrip-
tional activity of activator protein 1(AP1) in the signaling
cascade of JNK and MAPK [9]. In the dog, P4 also plays
an important role in mammary cancer [10]. This makes
dogs a useful model, since they share human environmen-
tal risk factors and their mammary tumor biology shows a
significant overlap with humans: sequencing canine simple
mammary carcinomas revealed comparable genomic aber-
rations to those in human breast cancer. Further, both
humans and dogs apparently share pathways that are
altered in carcinogenesis, such as cell adhesion, Wnt
signaling and PI3K signaling [11], making them an at-
tractive model for hormone-dependent breast cancer
research [5, 12].
Recently we have shown that three canine mammary
tumor cell lines with high basal Wnt/β-Catenin activity do
not respond to treatment with the Wnt ligand synthesis
inhibitor IWP-2 and therefore use a ligand-independent
mechanism to activate the pathway. In 4 other cell lines,
moderate basal Wnt reporter activity could be inhibited
using IWP-2 showing a clear ligand depend Wnt activity,
the remaining cell lines had no basal Wnt activity. We fur-
thermore showed that overexpression of LEF1 is one of
the contributing factors of the high Wnt/β-Catenin activ-
ity in these cells [5]. In this study we demonstrate that
these cells also have lost PTEN expression. PTEN is a
tumor suppressor gene and a phosphatase that antago-
nizes the kinase activity of PI3K. PTEN can also target
focal adhesion kinase (FAK), the EGF receptor and itself
as a binding partner to increase p53 activity [13]. A prop-
erly functioning PTEN thus inhibits PI3K/AKT/mTOR
and MAPK signaling.
The epidermal growth factor (EGF) is transactivated
by the Wnt pathway, which in addition stimulates the ß-
catenin/TCF pathway, making Wnt a potent oncogene
in the mammary gland [14]. Binding of EGF or related
growth factors to the EGF receptors induces homo- and
heterodimers leading to phosphorylation on specific
tyrosine residues; these residues serve as docking sites
for a variety of signaling molecules, leading to activation
of intracellular pathways such as the mitogen-activated
protein kinase (MAPK), the phosphatidylinositol-3-
kinase (PI3K), Stats, RAS and cSRC pathways. Although
not binding any ligand, HER2 plays a central role to-
gether with the HER3 protein that lacks proper tyrosine
kinase activity, with this complex being the strongest ac-
tivator for downstream signaling pathways [14, 15].
HER3 can also signal ligand independent and its activa-
tion is associated with resistance to HER2 targeting tyro-
sine kinase inhibitors in breast cancer [16]. The HER3
protein, which has no kinase activity, may signal in the
nucleus through several C-terminal transactivation do-
mains [17]. Also in the dog, HER2 is overexpressed in
some 35 % of malignant mammary tumors whereas
HER3 is found in the nucleus of some 42 % of mammary
carcinomas [18].
We therefore investigated in a panel of canine mam-
mary tumor cell lines for a relationship between the ca-
nonical Wnt signaling and HER signaling pathways. As
shown recently these cell lines varied in basal Wnt/ß-
Catenin signaling from high ligand-independent to mod-
erate ligand-dependent or absent basal [5].
Methods
Canine mammary cell lines and culture
Canine mammary tumor cell lines used in this study were
CMT1, CMT-U229, CMT-U335, CMT-U27, CMT9, P114,
CHMp, CHMm, CNMp, CNMm, CIPp and CIPm [19–21].
The cell lines were generous gifts of the Prof Dr Hellmen
(SLU, Uppsala, Sweden), Prof Dr Sasaki (Laboratory of
Veterinary Surgery, University of Tokyo, Japan), and Dr
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Rutteman (Utrecht University, The Netherlands). All cell
lines were cultured in DMEM/F12 (Invitrogen, Bleiswijk,
The Netherlands) supplemented with 10 % fetal bovine
serum (FBS) (FBS Gold, PAA, Cӧlbe, Germany). Cells were
tested to be free from mycoplasma with a Mycosensor
QPCR assay according to manufacturer’s protocol (Agilent
technologies, Middelburg, The Netherlands).
TCF-reporter assay
Cells were seeded in a 24 well plate (Primaria, BD Bio-
sciences, Breda, The Netherlands) at a density of 100,000
CMT1, CMT-U27 and CMT9 cells and 80,000 CIPm cells,
to reach an 80 % density 24 h before transfection. Trans-
fection was performed in FBS-free medium using 3 μl Li-
pofectamine 2000 (Invitrogen), 800 ng pTOPFLASH
(TOP) or pFOPFLASH (FOP) (gift from Prof Dr Hans
Clevers, Hubrecht Institute, The Netherlands) and 0.5 ng
human ß-actin-promoter renilla construct [22] as an in-
ternal control. Transfection was stopped after 5 h by add-
ing the same volume DMEM/F12 supplemented with 20 %
FBS. Cells were treated with 100 nM Everolimus (Selleck-
chem, Munich, Germany), 50 nM BEZ235, (Selleckchem),
20 μM Src-I1 (Enzo, Lausen, Zwitserland), or 1 μM FAK
Inhibitor 14, (Santa Cruz, Heidelberg, Germany) for 40 h.
All the compounds were dissolved in DMSO and diluted
in medium to a final concentration of 0.2 % DMSO. The
firefly and renilla luciferase activities were measured using
a Dual-Luciferase Assay System (Promega, Leiden, The
Netherlands) in a Centro LB 960 luminometer (Berthold
Technologies, Vilvoorde, Belgium).
Real time quantitative RT-PCR
From each cell line, total RNA was isolated and treated
with DNase using RNeasy mini kit (Qiagen, Venlo, The
Netherlands) according to manufacturer’s protocol. Using
iScript kit (BioRad, Veenendaal, The Netherlands), cDNA
synthesis was performed. Specific primer sets were used
to amplify gene products in a qPCR reaction (Table 1).
The reactions were performed and measured using a
BioRad MyIQ detection system (BioRad) with SYBR green
fluorophore. Relative target gene expression was normal-
ized to a set of eight reference genes (tested in Genorm
with a pairwise variation (PV) of 0.07) for the transfection
experiments. For the cluster analysis, 6 reference genes
were used with a PV 0.07 (HNRPH, TBP, SRPR, HMBS,
RPS5 and RPS19). A relative induction of gene expression
was statistically assessed using paired, 2-tailed student’s T-
test. Relative expression was calculated by the delta-delta
Ct (ΔΔCt) method [23].
Cell viability
Cell viability was determined by means of the colorimet-
ric 3-[4,5-dimethylthiazol-2-yl] 2,5-diphenyltetrazolium
bromide assay (MTT) (Sigma Aldrich, Zwijndrecht, The
Netherlands). Briefly, cells were seeded in 96 wells plates
(Primaria, BD Biosciences, Breda, The Netherlands) and
after 24 h incubation to attach and stretch, treated with
the different compounds for 40 h. Cell viability was de-
termined by incubating 20 μl 5 mg/ml MTT in 100 μl
medium in each well. After a 2 h incubation, the media
was removed by decanting and 100 μl DMSO was added
to each well, incubated for 30 min and the absorbance
was measured at 595 nm in a spectrophotometer
Anthos Multimode Detector (Anthos Mikrosystem
GmbH, Krefeld, Germany). IC50 curves were plotted
with Sigma-plot version 12.5.
Protein extraction and Western blot
Cells were seeded in 75 cm2 bottles and after 24 h incuba-
tion to attach and stretch, treated with the different com-
pounds. After 40 h cells were washed with cold HANK’s
balanced salt solution and lysed and scraped with RIPA
buffer [5]. After 20 min incubation on ice, samples were
centrifuged for 15 min at 16,000 g and 4 °C. Protein con-
centration was determined using Bio-Rad Dc Protein
Assay (Bio-Rad Laboratories). Twenty micrograms of pro-
tein from total cell lysates was subjected to SDS-PAGE
and analyzed by Western blot. Primary antibodies used in
this study were directed against β-Catenin (Ab6302
1:4000) (Abcam, Cambridge, UK), HER2 (PA5-14635
1:500) (Pierce-Thermo Scientific), HER3 (PA1-86644
1:2500 (Thermo Scientific), with β-Actin pan Ab-5 (MS-
1295-P1 1:2000) (Thermo Scientific) as a reference
protein. And as secondary antibody, goat anti-mouse
HRP-conjugated (HAF007), goat anti-rabbit HRP conju-
gated (HAF008) and donkey anti-goat HRP conjugated
(HAF109) (R&D Systems, Abingdon, UK) was used in a
1:20.000 dilution. HRP was visualized using Advance
TM_Enhanced chemiluminescence (ECL, Amersham, GE
Healthcare, Eindhoven, The Netherlands) and analyzed
using GelDoc 2000 (Bio Rad). With the Quantity One
software, version 4.6.9 (BioRad), densities were measured,
corrected for the background and related to β-Actin ex-
pression as loading control.
Statistics
Cluster analysis with qPCR results from all the cell lines
was done in RStudio (version 3 software (R Core Team
(2013) R: A language and environment for statistical
computing. R Foundation for Statistical Computing,
Vienna, Austria; http://www.R-project.org)) with a Pear-
son:Spearman test (genes: Pearson; samples: Spearman
average) to find a correlation between the TOP/FOP ra-
tio, related target genes and the cell lines.
Transfection and incubation studies, and also the MTT
assays, were done in three independent experiments (n = 8
for MTT and n = 4 for each transfected/incubation
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compound). After background subtraction, the cell via-
bility, the Wnt-signaling and the protein levels were
calculated as a percentage of the non-treated cells.
IC50 curves were done in a single experiment with n =
8 and the HER3 Western blots were done in triplicate.
Differences in TOP/FOP activities, RNA, cell viability
and protein expression levels were statistically assessed
using unpaired, two tailed Student’s t test, a P value less
than 0.01 was considered significant.
Results and discussion
Wnt activity and gene clustering
In a continuation of our previous findings of a variation
in basal Wnt/β-Catenin activity in canine mammary
tumor cell lines [5] we searched for the mRNA expres-
sion of members of the EGF receptor family of proteins
and the associated signal-transduction pathways. In the
present paper, the three cell lines with high ligand-
independent basal Wnt activity (CMT1, CMT-U27 and
CMT9) were, through cluster analysis of the gene ex-
pression data, shown as a clear grouping, but no clear
association for absent or low Wnt-ligand induced basal
Wnt/β-Catenin activity in the other cell lines (Fig. 1).
High basal Wnt activity is clearly grouped together with
an up-regulated expression of LEF1, ID1, ID2, EGFR
(only in CMT1), HER2/3, HSP90 and RAC1 mRNA and
a down regulation of SLUG, NCOA3, MUC1, CYCLIN
D1, BCL2, cMET and PTEN mRNA. In these highly acti-
vated Wnt cell lines, PTEN expression is completely lost.
PTEN deficiency occurs in 5 to 14 % of primary human
breast cancers and PTEN is also lost in human T47D
and MCF7 cell lines [13]. The cluster analysis confirmed
our previous finding that in the cell lines with active
Wnt signaling, LEF1 is overexpressed and acts as a
Table 1 Primers used






CTNNB1 β-Catenin ATGGGTAGGGCAAATCAGTAAGAGGT AAGCATCGTATCACAGCAGGTTAC 64.0 106 XM_005634157.1
AXIN2 Axin2 GGACAAATGCGTGGATACCT TGCTTGGAGACAATGCTGTT 60.0 141 XM_548025
BNIPL BCL2 TGGAGAGCGTCAACCGGGAGATGT AGGTGTGCAGATGCCGGTTCAGGT 62.0 87 AY_509563.1
CCND1 CYCLIND1 GCCTCGAAGATGAAGGAGAC CAGTTTGTTCACCAGGAGCA 60.0 117 NM_001005757.1
ERBB1 EGFR CTGGAGCATTCGGCA TGGCTTTGGGAGACG 53.0 107 XM_533073
ERBB2 HER2 CGTGCTGGACAATGGAGACC CCGCTGAATCAAGACCCCTC 64.0 51 AB008451
ERBB3 HER3 TAGTGGTGAAGGACAACGGCAG GGTCTTGGTCAATGTCTGGCAG 70.0 103 XM_538226
HSP90AA1 HSP90 CTTGACCGATCCCAGTAAGC TATTGATCAGGTCGGCCTTC 59.0 127 XR_134513.2
ID1 ID1 CTCAACGGCGAGATCAG GAGCACGGGTTCTTCTC 59.5 135 XM_847117.2
ID2 ID2 GCTGAATAAATGGTGTTCGTG GTTGTTCTCCTTGTGAAATGG 60.5 114 XR_134413.1
TCF7L3 LEF1 AGACATCCTCCAGCTCCTGA GATGGATAGGGTTGCCTGAA 60.0 137 XP_863334.2
MET cMET TGTGCTGTGAAATCCCTGAATAGAATC CCAAGAGTGAGAGTACGTTTGGATGAC 56.0 159 NM_001002963.1
MUC1 MUC1 CTATGAGGAGGTTTCTGCAG GAACACAGTTGAGAGGAGAG 62.0 172 NM_001194977
NCOA3 NCOA3 ATGCGGCCTGGTGAGATT TAAGAAGTGGCCTATTTTGAGTCC 67.1 141 ENSCAFT00000017243
PTEN PTEN AGATGTTAGTGACAATGAACCT GTGATTTGTGTGTGCTGATC 62.0 102 NM_001003192.1
RAC1 RAC1 TCCCTTATCCTATCCGCAAA ATGATAGGGGTGTTGGGACA 58.0 128 NM_001003274.2
RAC1B RAC1b TGGGATACAGCTGGACAAGA CTTGTCTTTGCCCCTGGAG 58.0 108 JN_182651.1
SNAI2 SLUG CTTCACTCCGACTCCAAACG TGGATTTTGTGCTCTTGCAG 60.0 147 XM_005637933.1
Reference genes
HMBS HMBS TCACCATCGGAGCCATCT GTTCCCACCACGCTCTTCT 61.0 112 XM_546491
HNRNPH2 HNRPH CTCACTATGATCCACCACG TAGCCTCCATAACCTCCAC 61.2 151 XM_538576
HPRT1 HPRT AGCTTGCTGGTGAAAAGGAC TTATAGTCAAGGGCATATCC 57.0 104 NM_001003357
RPS5 RPS5 TCACTGGTGAGAACCCCCT CCTGATTCACACGGCGTAG 62.5 141 XM_533568
RPS19 RPS19 CCTTCCTCAAAAAGTCTGGG GTTCTCATCGTAGGGAGCAAG 62.0 95 XM_533657
SRPR SRPR GCTTCAGGATCTGGACTGC GTTCCCTTGGTAGCACTGG 61.2 81 XM_546411
TBP TBP CTATTTCTTGGTGTGCATGAGG CCTCGGCATTCAGTCTTTTC 57.0 96 XM_849432
YWHAZ YWHAZ CGAAGTTGCTGCTGGTGA TTGCATTTCCTTTTTGCTGA 58.0 96 XM_843951
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contributing factor of the high canonical Wnt pathway
[5]. New is our finding of a strong association of the
expression of the EGF pathway both at the receptor
level (HER expression) as in the silencing of PTEN
with high ligand independent Wnt signaling. Pre-
viously, it has been shown that binding of Wnt pro-
teins to the Frizzled receptor may activate the EGFR.
EGFR can be further activated by homo or hetero-
dimerization with HER2, HSP90 as its chaperone, or
HER3. These activated complexes functions as an
oncogenic unit to drive the proliferation of breast
cancer cells [14, 24]. In human and mouse mammary
glands, the activated Wnt/β-Catenin is related to en-
hanced HER2 expression [25], something also found
in 30 % of canine malignant mammary tumors [26].
Combining the up regulation of both HER2 and
HER3 in our canine mammary cell lines and the fact
that the HER2/HER3 complex is the strongest activa-
tor for downstream signaling pathways makes this an
interesting area for further research [15, 27, 28].
We concluded that the association between high Wnt
signaling (high TOP/FOP ratios), high LEF1 levels, loss
of PTEN and high HER2/3 mRNA levels all point to the
activation of the PI3K/AKT/mTor pathway [29–32].
We therefore investigated the effects of PI3K/mTor
inhibitors on cell viability, Wnt signaling, expression
levels of the differently expressed genes from the clus-
tering analysis and the cellular content of β-Catenin,
and HER2/3 protein as an experimental model for
HER2+/PTEN- breast cancer.
Fig. 1 Cluster analysis of different canine mammary cell lines with their relative basal gene expression. RNA from 12 different canine mammary cancer
cell lines was isolated and quantitative RT-PCR was done for several target and reference genes on their cDNA. RT-PCR data were analyzed in RStudio
with the Pearson:Spearman test and graphically presented with their corresponding TOP/FOP ratios (blue >30; dark grey 2-6; light grey <2) as published
previously [5]. The three cell lines with high basal TOP/FOP ratios (canonical Wnt pathway) cluster together in the non-hierarchical cluster analysis. Green
is a high expressed gene and red is low expressed gene
Timmermans-Sprang et al. BMC Cancer  (2015) 15:545 Page 5 of 12
PI3K/mTor inhibition decreases cell viability but
stimulates Wnt activity
Cell lines with high Wnt activity and a cell line lack-
ing basal Wnt activity (CIPm) were incubated with
Everolimus as a specific mTor inhibitor and BEZ235
as a dual inhibitor of PI3K and mTOR. Both BEZ235
and Everolimus equally inhibited the viability of the
highly activated Wnt cell lines and have only a
slightly inhibitory effect on the CIPm cells (Fig. 2).
This inhibitory effect on viability was clearly dose-
dependent and present in both the high basal Wnt cell
line CMT-U27 and the CIPm cell line (Fig. 3 and Table 2).
Comparable concentrations of BEZ235 were also used in
human studies with different cell lines [33, 34]. In human
MCF7 cells, Everolimus (Rad001) was tested in a range
from 0-1000 nM and only the 1000 nM concentration
showed a 50 % reduction in cell number [35]. Incubation
of these cells with BEZ235 and Everolimus resulted in un-
expected further significant enhancement of Wnt activity
of CMT1, CMT-U27 and CMT9, with a more than 2-fold
increase in the TOP/FOP ratios (Fig. 4).
BEZ235-induced inhibitions of cell proliferation have
been reported previously in MCF-7/shPTEN cells and in
21 other tested human cancer cell lines [13]. The only
difference is that in these cell lines, BEZ235 had a stron-
ger effect than Everolimus on cell proliferation [36]. In
human breast cancer, loss of PTEN is associated with ac-
tivation of the PI3K/AKT Pathway [12], which may re-
sult in increased nuclear stabilization of β-Catenin in
mammary stem cells using human breast tissue xeno-
grafts [37]. This is in contrast to the absence of any in-
hibitory effect in the TOPFlash reporter assays of several
breast and prostate cancer cell lines treated with another
inhibitor of the PI3K pathway (Wortmannin) and sug-
gests that the PI3K pathway has no relation with Wnt-
mediated transcriptional activity [30]. In our cell lines as
well, neither Wortmannin nor the introduction of a
PTEN-expressing plasmid inhibited Wnt signaling, indi-
cating that PI3K inhibition alone does not influence the
active Wnt signaling and that mTor inhibition is needed
(data not shown). CIPm, which lacks basal Wnt activity,
did not respond to both inhibitors with increased re-
porter activity.
We conclude that inhibition of PI3K and/or mTor
in the highly activated Wnt cell lines inhibits cell via-
bility, but further stimulates Wnt activity. Because the
mechanism behind this remained unclear, we tested
the effect of these inhibitors on the expression of
genes from the cluster analysis.
PI3K/mTor inhibitors stimulate β-Catenin, Axin2, MUC1,
cMET, EGFR and HER2 expression in the activated Wnt cell
lines
Inhibition of the PI3K/mTor pathway with BEZ235 (a dual
PI3K mTor inhibitor) or with Everolimus (a single mTor
inhibitor) in cell lines with high ligand-independent canon-
ical Wnt activity resulted in comparable upregulation of a
number of candidate genes (Fig. 5). A moderate twofold
Fig. 2 Effects of drugs on cell viability. Cell viability (MTT assay) was measured after treatment with PI3K/mTor inhibitor BEZ235, mTor inhibitor
Everolimus and cSRC inhibitor Src-l1. Three cell lines with a high TOP/FOP ratio (>30) (CMT1, CMT-U27, and CMT9) and CIPm cells with a low
TOP/FOP ratio (<2) were grown for 40 h in the presence of PI3K/mTor inhibitor BEZ235 (50nM), mTor inhibitor Everolimus (100nM) and cSRC
inhibitor Src-l1 (20 μM). After 40 h the cell numbers were measured with a MTT assay. Results expressed as % of control are the mean (±STDEV)
of three independent experiments. *P < 0.01 versus appropriate cell line control (DMSO)
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increase was detected in the expression of β-Catenin,
Axin2, HER2 and cMet mRNA. Only the expression of
EGFR and MUC1 mRNA was higher, especially in the
CMT-U27 and CMT9 cell lines. β-Catenin and Axin2 are
markers for an activated Wnt/β-Catenin signaling in mam-
mary tissues [38]. Protein levels of β-Catenin were not sig-
nificantly different after treatment with both inhibitors
(Fig. 6). The stable total protein expression of β-Catenin
may reflect predominantly binding to E-cadherin, which is
comparable high in both cell lines [5, 7] and may not be re-
lated to the cytoplasmic or nuclear ß-Catenin content. No
significant effect of both inhibitors was seen on HER2/3
protein content although HER3 expression was only found
in the cell line with high basal Wnt activity (Fig. 6). Apart
from the expression of HER2 at the cell surface it can also
form a complex with AP-1/Stat3/PR in the nucleus. This
nuclear HER2 can act as a transcription factor and modu-
late genes involved in breast cancer proliferation [9]. In
contrast with the absence of HER3 in the CIPm cell line,
the CMT-U27 cells have a HER3 band visible at 180kD,
which correspond to a glycosylated form. This glycosylated
HER3 protein is also found in human MDA-MB-445 and
MDA-MB-453 cells [39]. In MDA-MB-453 and other
mammary tumor cell lines, there is strong evidence for the
role of HER3 in cancer. HER3 plays a role in EMTand acti-
vated HER3 can also increase the expression of the cMET
proto-oncogene independently from EGFR and HER2 [16],
which may be in line with the 2-3 fold increased expression
shown in Fig. 5. EGFR and HER2 expressions are upregu-
lated after treatment with BEZ235 in a human breast can-
cer cell line with a lack of PTEN (MDA-MB-468). In
contrast with this BCL2 is not upregulated in all tested ca-
nine cell lines and HER3 is only, although significantly, 1.5
times upregulated in some cases [40]. The most prominent
change was the 7-fold increase inMUC1 expression. At the
same time, in all tested cell lines, basal MUC1 protein con-
centrations showed no difference, even in the presence of
considerable amounts of the cytoplasmic domain MUC1-
CD (data not shown). Still, overexpression of MUC1 plays a
role in tumor formation and progression in > 90 % of the
breast cancers [41]. It has been reported that the Wnt activ-
ity is directly affected through the binding of the Wnt ef-
fector β-Catenin on MUC1-CD [42] through binding of
several proteins, including cMET, cSRC and EGFR/HER.
Consistent with this is the enhanced EGFR and oncoprotein
MUC1 mRNA concentrations in our experiment together
with the upregulation of cMET. Enhanced cMET expres-
sion has been linked to poor prognosis in human
breast cancer, since it influences extravasation/angio-
genesis, enhances resistance to endocrine therapy and
trastuzumab treatment and may influence the regula-
tion of β-Catenin/TCF transcription [29, 43]. The basal
expression of cMET in the cell lines with elevated Wnt
activity is low, but stimulated when the PI3K/mTOR
pathway is blocked; blocking this pathway also affects
the EGFR and HER2 expression. Overexpression of
MUC1 is associated with the induction of anchorage-
independent growth and tumorigenicity in human
carcinomas. MUC1 overexpression is also directly as-
sociated with stabilization of β-Catenin either via
MUC1 binding to E-Cadherin, or by inhibition of the
adenomatous polyposis coli (APC)/GSK3β/ MUC1-
CD complex, whereas phosphorylation of MUC1-CD
by EGFR and cSRC increases β-Catenin [42, 44–46].
Leaving aside the question of how EGFR/HER2/HER3
signaling is involved in high basal Wnt activity, it is clear
Fig. 3 IC50 curves. CMT-U27 (high TOP/FOP ratio, >30) and CIPm cells
(low TOP/FOP ratio, <2) were grown for 40 h with the three inhibitors,
BEZ235 (a), Everolimus (b) and Src-l1 (c) in increasing concentrations
(BEZ235 0.1nM–100 uM, Everolimus 0.01 nM–10 μM and Src-I1 0.1
μM–20 μM). After 40 h the cell viability was measured with a MTT
assay. Results, expressed as % of control, are the mean (±SEM) of three
independent experiments. *P < 0.01 versus appropriate cell line
control (DMSO). IC50 values were calculated with Sigma-Plot
software (version 12.5)
Table 2 IC50 values for inhibition of cell proliferation
Inhibitor IC50 proliferation Concentration used References
CIPm CMT -U27
BEZ235 69 nM 29 nM 50 nM [33, 34]
Everolimus 3 nM 1 nM 100 nM [35]
Src-I1 4 μM 1 μM 20 μM [49]
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that the upregulation of the MUC1 and EGFR/HER2 ex-
pression have a relationship with the increased Wnt
activity that occurs after inhibition of the PI3K/mTor
pathway. The presence of glycosylated HER3 protein in
the highly activated Wnt cell line is new, and because
our results suggest that activation of cSRC could play a
role [15, 46], we next studied the influence of cSRC in-
hibitors on the Wnt activity and HER3 levels.
Active Wnt signaling significantly inhibited by the cSRC
inhibitor Src-I1
Activation of EGFR initiates the activation of PI3K/
AKT/mTor and MAPK as well as various other signaling
pathways, including the PLC-Υ1, JAK/STAT, and cSRC
pathway [15, 47]. Because the EGFR can form a complex
with cSRC, FAK (focal adhesion kinase), integrins and β-
Catenin resulting in growth, viability, survival and mi-
gration [46], we tested the effect of the cSRC inhibitor 1
(Src-I1) and a FAK inhibitor [48, 49]. Treatment with
the FAK inhibitor resulted in a small non-significant
decreases in the TOP/FOP ratio with no effect on cell
proliferation (data not shown), however Src-I1 had a
clear effect on cell viability and was found to be an
inhibitor of the Wnt activity via inhibition of cSRC
signaling [50, 51]. The same inhibition on the Wnt
pathway was found in the human cell lines NIH 3 T3
with the cSRC inhibitor PP1 [52]. The used concen-
tration of Src-I1 reduced cell proliferation for some
20 % and acted as a weaker inhibitor in comparison
with BEZ235 and Everolimus (Fig. 2). Unlike BEZ235
and Everolimus, the cSRC inhibitor Src-I1 reduced
the Wnt/β-Catenin signaling by almost half in canine
mammary tumor cell lines with high canonical Wnt
activity, but not in the CIPm cells that lack basal
Wnt activity (Fig. 4). Inhibiting mouse cells with
cSRC inhibitors PP2 and Genistein gave comparable
results on LEF/TCF sensitive transcription and on the
level of activated phosphorylated cSRC. This indicates
that cSRC is a positive regulator of the Wnt/β-Catenin
signaling [50]. To investigate the Wnt-regulation by both
the PI3K pathway and the cSRC pathway, we tested the
same target genes used in the clustering analyses (Fig. 1).
Effects of cSRC inhibition on gene and protein expression
The cSRC inhibitor Src-l1 decreased the cell viability
(Fig. 2), decreased Wnt signaling (Fig. 4) without affecting
MUC1, EGFR and HER2/HER2 expression levels
(Figs. 5 and 6). The inhibition of Wnt activity as mea-
sured by a decrease in TOP/FOP ratios was also
clearly dose-dependent (data not shown) in the
Fig. 4 Effects of drugs on Wnt signaling. PI3K/mTor inhibitor BEZ235 and mTor inhibitor Everolimus stimulates the TOP/FOP ratios. Incubation
with the cSRC inhibitor Src-l1 shows a down regulation of the Wnt reporter activity. Three cell lines with a high TOP/FOP ratio (>30) (CMT1,
CMT-U27, and CMT9) and CIPm cells with a low TOP/FOP ratio (<2) were grown for 40 h in the presence of PI3K/mTor inhibitor BEZ235 (50nM),
mTor inhibitor Everolimus (100nM) and cSRC inhibitor Src-l1 (20 μM). After 40 h the TOP/FOP ratio was measured with a Dual-Luciferase assay.
The mean ratio is expressed of three independent experiments (±SEM). *P < 0.01 versus appropriate cell line control (DMSO). PI3K/mTor inhibitor
BEZ235 and mTor inhibitor Everolimus stimulates the TOP/FOP ratios. Incubation with the cSRC inhibitor Src-l1 shows a down regulation of the
Wnt activity in the basal activated Wnt cell lines
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activated Wnt cells. Marginal increases were found in
SLUG and HER3 mRNA concentrations (Fig. 5c) after
cSRC inhibition. Remarkably inhibition with Src-I1 showed
a significant decrease in HER3 protein concentrations
whereas the HER3 mRNA expression was slightly elevated
indicating that cSRC inhibition is associated with a higher
turnover or a decreased glycosylation of HER3 at the
protein level. At the moment information on the
regulation of HER3 expression is scarce. Several
microRNAs regulate the expression levels and also
epigenetic effects have been shown to influence HER3
expression in breast cancer cells [16].
Conclusions
We see an association between the Wnt pathway and
the EGFR/HER2/HER3 stimulated cSRC (motility) route.
The role of MUC1 is less clear and needs further
research. In mice, however, data are available showing
Fig. 5 Effects on gene expression. CMT1, CMT-U27 and CMT9 cells were grown for 40 h with the three inhibitors, 50nM BEZ235 (a), 100nM Everolimus
(b) and 20 μM Src-l1 (c). After inhibition RNA was isolated and the relative expression of several target genes was measured by quantitative RT-PCR.
The differences in expression levels compared to an appropriate control were expressed as the mean of 12 samples out three independent
experiments. *P < 0.01
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that MUC1 activates cSRC signaling by influencing the
association of PI3K and β-Catenin leading to a delay
in mammary tumor progression [46]. Prior research
indicates that activation of the PI3K/mTor pathway
may be related to resistance to hormonal therapies.
Administration of the mTor inhibitor Everolimus has
therefore been studied extensively in women with
HR+, HER2+ or TNBC breast cancer. Reports on
various studies, i.e. BOLERO (Breast Cancer Trials of
Oral Everolimus), TAMRAD and EFECT, have shown
an increased progression free survival (PFS) when
Everolimus was combined with aromatase inhibitors [53].
If the effects shown in this paper on the in vitro inhibition
of cell viability but increased Wnt signaling are also present
in a subset of breast cancer patients then treatment with
Everolimus could have an adverse effect on Wnt regulated
aspects such as stemness and metastasis.
cSRC may play a crucial role in tumor growth and metas-
tasis. Metastasis involves loss of cellular adhesion, increased
motility, intravasation, invasion, extravasation, resistance to
anoikis, and colonization at distant sites. High cSRC ex-
pression is found in various breast cancers in association
with reduced survival. Recently the cSRC inhibitors Dasati-
nib and Bosutinib were studied as a monotherapy in
humans, but showed no clear reduction of antitumor activ-
ity, indicating that before further studies are done, clear
biomarkers should be found for proper patient selection
[54]. The search for these biomarkers is being aided by re-
search on dogs with spontaneous mammary carcinomas.
For example, the successful treatment with Dasatinib of a
Fig. 6 Protein levels in CIPm and CMT-U27 inhibited with BEZ235, Everolimus and Src-I1. Cells were cultured for 40 h with the inhibitors, 50nM
BEZ235, 100nM Everolimus and 20 μM Src-l1. Total protein was isolated with RIPA buffer and 20 μg protein was used for Western Blot analyses.
Blots were probed with total antibodies for β-Catenin, HER2, HER3 and β-Actin (a). The HER3 blot was done in triplicate and normalized against
β-Actin. Results, expressed as % of control are the mean (±STDEV) *P < 0,05 versus DMSO control (b). Densities were measured, corrected for the
background and related to β-Actin expression as loading control, expressed in % (c)
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dog with osteosarcoma, reported in a recent case study,
shows that the dog is an interesting animal for further clin-
ical studies using cSRC inhibitors in HER2+/PTEN- tumors
[26, 55, 56]. Binding of cSRC to HER2 is crucial for the for-
mation of HER2:HER3 heterodimers. Both phosphorylated
and total levels of cSRC are upregulated in anti-estrogen re-
sistant T47D cell lines that show growth reduction by cSRC
inhibitors. EGFR homodimers also play an important role
in growth. The individual contributions of EGFR, HER2
and HER3 in Wnt pathway activation require further study.
Our results on highly activated Wnt signaling cells require
further research into the role of HER3, cSRC, and Wnt on
tumor growth and metastasis [57].
In summary, inhibition of the PI3K/mTor pathway in
tumor cell lines with ligand-independent Wnt activity
further increases canonical Wnt signaling. As we have
shown, this Wnt activity can be effectively inhibited by a
cSRC inhibitor. While very recently, loss of PTEN has been
associated with worse outcomes in HER2 positive breast
cancer patients, no data are available on their Wnt activity
[58]. Although a number of human breast cancer cell lines
have active ß-catenin signaling (summarized in [5]), this re-
lation between HER2/3 expression and PTEN loss appears
not to have been previously documented.
Further studies will need to identify optimal bio-
markers for selecting breast cancer patients most likely
to benefit from concerted treatment with combination
therapies of mTor and cSRC inhibitors. Such research is
very likely to include studies in dogs with spontaneous
mammary carcinomas.
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